Localized Scleroderma / Morphea (Investigational Adjunct)
Highly investigational adjunct for stable plaque morphea; no RCT evidence; UVA1 phototherapy and methotrexate remain primary for active disease.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for morphea (localized scleroderma). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- What evidence exists?
- Tier C (investigational). No controlled trials were found; the only clinical reports found are one 2-patient uncontrolled report of scleroderma of unspecified type and one Russian report with no patient numbers. Evidence-based first-line management of active morphea is topical or intralesional corticosteroid for limited plaques, calcipotriene-betamethasone for superficial disease, narrowband UVB or UVA1 phototherapy for widespread plaques, and methotrexate plus systemic corticosteroid for severe or rapidly progressive disease in pediatric and adult patients.
- Main risks
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Worsening of skin sclerosis (theoretical) from inflammatory bite sites
- Permanent dyspigmentation in already pigmented or hypopigmented plaques
- Who should not consider this
- Patients with active inflammatory morphea who have not had a trial of phototherapy or methotrexate
- Patients with linear or deep morphea affecting joint mobility (need rheumatology workup)
- Children with pansclerotic or coup-de-sabre variants (need aggressive systemic therapy)
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
- People with hemophilia or any other inherited bleeding disorder
- Patients with anemia
- People with an active infection at the planned application site
- What to ask your clinician
- Has my morphea subtype (plaque, linear, generalized, deep) been correctly classified by dermatology or rheumatology?
- Have I tried phototherapy (UVA1 or narrowband UVB)?
- Should methotrexate plus systemic steroid be tried for active disease?
- What is the published evidence base for leeches in morphea specifically?
- What is the risk of pigment changes or bite scarring on top of existing morphea?
- How will disease activity be monitored — clinical, ultrasound, both?
- When to seek urgent care
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Rapid expansion of a plaque, new joint contracture, or limb-length discrepancy (in children)
- New neurologic symptoms with coup-de-sabre lesions (rare but reported)
What this does NOT mean
- It does not mean leech therapy is FDA-cleared for morphea — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace phototherapy, methotrexate, or systemic corticosteroid for active disease.
- It does not stop the underlying fibrosing process driving morphea.
- It does not address functional or growth complications in pediatric linear or deep morphea.
- It does not have controlled-trial evidence in any morphea subtype.
Safety cross-references
Clinical Profile
- Category
- Dermatological
- ICD-10
- L94.0, L94.1
- Safety tier
- Medium
Evidence Summary
Localized scleroderma (morphea) is an autoimmune fibrosing disorder of skin and subcutaneous tissue. Active disease is treated per AAD and EUSCLE guidance with methotrexate (often with systemic corticosteroid bridge), UVA1 or narrowband UVB phototherapy, and topical calcipotriene plus high-potency steroid. A small uncontrolled Azerbaijan center series (Farzali 2025) reported 100 percent success, rated from post-treatment examination, patient feedback and physician evaluation, in n=2 patients with scleroderma of unspecified type, with skin thickening described as returning to normal; the sample size, lack of blinding, lack of a comparison group, unspecified subtype, and absence of objective sclerometric outcomes preclude conclusions about disease modification. A Russian clinical report published in a hirudology collection of articles (Rybakova 1998, as described in Baskova and Isakhanyan 2004) treated patients with the plaque form of scleroderma and other skin diseases with leeches and reported a favorable effect for the group as a whole (such as reduced erythema, infiltration and itching), but gave no patient numbers or scleroderma-specific results. Proposed mechanism centers on dampening dermal fibrogenic signaling via salivary peptides. No high-quality evidence supports use for active or extensive morphea.
What the books describe
Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.
- Baskova and Isakhanyan name scleroderma among the diseases in which leech treatment is recommended (noting that there are few publications on hirudotherapy in such conditions), and separately mention the plaque form of scleroderma; the words morphea, limited scleroderma or focal scleroderma do not occur in the book, so whether this form is meant is not clear from the text[B1].
- They retell a report by Rybakova (1998): hirudotherapy was prescribed to patients with the plaque form of scleroderma (the word “voluminous” before these words is not explained in the text) and also with chronic pyoderma, varicose eczema and eosinophilic granuloma of the face; the author, as retold, proceeded from the idea that skin changes are often a manifestation of malfunctions in the body[B1].
- The retelling stresses a marked favorable effect: in the lesions, as described, redness, infiltration and itching decreased, growth of pigmented hair began, and pain in the limbs disappeared; how many patients there were in all, how many of them had scleroderma, how long they were followed and whether they were compared with anyone is not stated, and the results for scleroderma are not singled out[B1].
- Michalsen et al. do not write about leech treatment of scleroderma; Flecken and Michalsen classify connective tissue diseases, along with immune diseases, as relative contraindications (among severe but stable chronic diseases) and do not name scleroderma, so whether this applies to the limited form is not clear from the text[B3].
- Among the contraindications, Baskova and Isakhanyan name hemophilia, hemorrhagic diatheses, anemias, low blood pressure and acute vascular insufficiency (shock, collapse, fainting), emaciation, concurrent use of anticoagulants (especially long-term and daily), concurrent use of alcohol, individual intolerance and an extremely negative attitude of the patient toward leeches, and at high body temperature they advise refraining from leeches[B1].
- Flecken and Michalsen, in the chapter on contraindications, call hemophilia and the use of anticoagulants an absolute contraindication, and in anemia and bone-marrow suppression, according to them, any treatment involving blood removal is generally contraindicated; aspirin and clopidogrel are not contraindications in themselves, but at the first session they advise reducing the number of leeches and asking the patient about a tendency to bleed[B3].
- In the appendix of Michalsen et al. (patient information and consent form), hirudotherapy is not performed, among other conditions, in blood diseases, acute gastric ulcer or erosive gastritis, immune deficiency (AIDS, chemotherapy), severe chronic diseases (advanced cancer, dialysis), a history of poor wound healing (for example, with poorly controlled diabetes, obesity and long-term cortisone treatment), known allergy to the active substances in leech saliva, and a tendency to keloids or scarring; the same document asks the patient not to use perfumed lotions, shower gels, medicinal ointments and oils on the day before and on the day of the procedure[B3].
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Key Trials
- Farzali S et al. (2025), n=2 · Turkiye Parazitol Derg · PMID 40923484 · ASH analysis →
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Active morphea (violaceous border, peripheral erythema, expansion)
- Linear morphea en coup de sabre or pansclerotic morphea
- Generalized morphea with systemic features
- Pediatric morphea (refer to pediatric rheumatology)
Related Conditions
Lichen Sclerosus (Investigational Adjunct)
Highly investigational adjunct for refractory lichen sclerosus; one small uncontrolled series (vulvar), no RCT; clobetasol remains standard of care.
Cutaneous Lichen Planus (Localized)
Investigational use for localized cutaneous lichen planus refractory to topical corticosteroid; very limited case-report evidence.
Livedo Reticularis
Investigational use for primary livedo reticularis; no clinical study was identified. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; no study in this condition was identified, only small series in venous ulcer and varicose disease.
References
- [B1]
Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]
Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.
- [B3]
Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy
ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.
The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.